CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
Penetration Testing In Healthcare: Common Vulnerabilities And Programs To Address Them
Explore some of the common pitfalls witnessed in healthcare environments, as well as guidance for implementing a penetration testing program.
-
Penetration Testing In Healthcare: HIPAA And GDPR Requirements
Learn about penetration testing requirements in the healthcare environment, including clinical research, according to HIPAA and GDPR.
ECOA RESOURCES
-
Discover how forward- thinking life science companies are defining their vision and looking for like-minded partners to execute information technology.
-
Central eSource transforms the conduct of clinical trials by replacing disparate, site-specific source templates with a unified, sponsor-designed framework.
-
TransPerfect Life Sciences' C3 Summit brings to you virtual sessions on how the paper to digital migration is evolving, the use and application of eCOA migration technology, and setting up successful eCOA solutions.
ECONSENT RESOURCES
-
Sites are frequently overwhelmed with the sheer number of technologies they must work with to conduct a clinical trial, and this aggregation platform can streamline trial management.
-
Read how five Florence employees with clinical research backgrounds came together to craft a checklist designed to walk sites through the process of tech-enabled study start-up.
-
This one-minute video highlights the benefits of One Home for Sites. Join the movement to increase clinical trial capacity, because patients are waiting.
EPRO RESOURCES
-
Dr. Anthony Everhart (Clinical VP, Signant Health) and Tim Meyer (Professor, University College London) discuss opportunities for increasing the usefulness of PROMs.
-
Signant’s patient and site research enhances digital health technology in clinical trials by optimizing usability and design. These insights drive improvements in product features, study designs, and training materials.
-
Explore the challenges pharmaceutical companies face in implementing PROs in cancer clinical trials as outlined in the FDA’s draft guidance, as well as strategies to overcome these obstacles.